Bioinformatic analysis revealed that 44.2% of these HLA-I alleles, spanning 92.4% of glioma patients, potentially presented a variety of different peptides encompassing RCAN1-4 SJe4/e5 (Supplementary Fig. 5D). This evidence concerns the gene RCAN1 and glioma.